Suraksha Diagnostic Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,647 Cr
- P/E
- 46.01
- ROE
- 14.21%
- PEG
- 0.74
- Price to sales
- 5.07
- Debt to equity
- 0.53
- 52W high / low
- ₹356 / ₹228
- Sales growth (5Y)
- 17.26%
- EBITDA margin
- 31.37%
- Net profit margin
- 10.19%
- Promoter holding
- 49.10%
- Sales (last year)
- ₹325 Cr
Guidance scorecard · Q1 FY27 call
What Suraksha Diagnostic Ltd's management guided
RevenueQ1 FY27 call
10–20%- The company expects steady revenue growth, targeting around 15% annually, reflecting a conservative approach as they mature their operations.
- Test volume growth has been robust historically (~20% YoY), though recent quarters showed some moderation (~10-11%). Volume growth remains a key driver.
- Expansion plans include adding approximately 20 new labs in FY '27, with about 50% of new centers in newer geographies beyond core regions like Kolkata and West Bengal.
- Genomics business is seen as a significant growth pillar, with strong adoption and market education efforts underway; expected to contribute meaningfully over the next 3-4 years.
- Mature centers showed ~12.5% revenue growth quarter-on-quarter, expected to sustain this momentum.
2 more points from Suraksha Diagnostic Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Suraksha Diagnostic Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Genomic Capacity Investment: Rs. 22 crores invested over 3 years in genomic labs.
- Future Genomics Capex: No substantial incremental CapEx expected in genomics for the next 2-3 years; existing CapEx is sufficient to leverage growth.
- FY '27 Capex Outlook: Rs. 70-80 crores planned for the financial year for network expansion.
- Center Expansion: Plan to open 6 spokes and 3 hubs in the current year, beyond centers already opened.
2 more points from Suraksha Diagnostic Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
Ask what Suraksha Diagnostic Ltd said on fundraising →
Full Q1 FY27 analysisOrder bookQ1 FY27 call
- The company is on track to open 100 centers by FY '28, indicating a strong expansion pipeline.
- Plans to add approximately 20 labs in FY '27, with about 50% in new geographies beyond Kolkata and West Bengal.
- Genomic testing capacity has been significantly invested in (Rs. 22 crores over 3 years) with expectations of strong growth.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Financials of Suraksha Diagnostic Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Suraksha Diagnostic Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 60.05 | 51.82 | 55.19 | 60.73 | 66.75 | 59.51 | 65.09 | 72.59 | 78.73 | 77.69 | 81.41 |
| Expenses + | 39.22 | 36.50 | 35.72 | 40.12 | 43.55 | 41.26 | 45.91 | 48.85 | 54.61 | 54.53 | 57.04 |
| Operating Profit | 20.83 | 15.32 | 19.47 | 20.61 | 23.20 | 18.25 | 19.18 | 23.74 | 24.12 | 23.16 | 24.37 |
| OPM % | 34.69% | 29.56% | 35.28% | 33.94% | 34.76% | 30.67% | 29.47% | 32.70% | 30.64% | 29.81% | 29.93% |
| Other Income + | 0.56 | 0.85 | 0.20 | 1.12 | 1.31 | 0.60 | 0.82 | 0.91 | 0.85 | 0.62 | 0.79 |
| Interest | 2.48 | 2.03 | 2.08 | 2.22 | 2.13 | 1.98 | 2.06 | 2.70 | 2.78 | 3.16 | 3.92 |
| Depreciation | 7.95 | 7.92 | 8.36 | 8.99 | 8.75 | 8.83 | 8.73 | 9.48 | 10.14 | 10.56 | 11.26 |
| Profit before tax | 10.96 | 6.22 | 9.23 | 10.52 | 13.63 | 8.04 | 9.21 | 12.47 | 12.05 | 10.06 | 9.98 |
| Tax % | 24.00% | 27.01% | 31.53% | 27.00% | 25.53% | 25.62% | 22.15% | 26.46% | 26.72% | 28.03% | 38.28% |
| Net Profit + | 8.34 | 4.53 | 6.32 | 7.67 | 10.15 | 5.98 | 7.17 | 9.18 | 8.83 | 7.24 | 6.16 |
| EPS in Rs | 121.88 | 67.39 | 94.49 | 1.84 | 2.40 | 1.18 | 1.42 | 1.80 | 1.73 | 1.44 | 1.21 |
Financials of Suraksha Diagnostic Ltd
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 158 | 140 | 223 | 190 | 219 | 252 | 310 |
| Expenses + | 123 | 115 | 175 | 143 | 146 | 170 | 215 |
| Operating Profit | 34 | 25 | 48 | 47 | 73 | 82 | 95 |
| OPM % | 22% | 18% | 22% | 25% | 33% | 33% | 31% |
| Other Income + | 2 | -1 | 2 | 1 | 1 | 4 | 3 |
| Interest | 2 | 2 | 2 | 10 | 10 | 9 | 13 |
| Depreciation | 13 | 16 | 15 | 32 | 33 | 35 | 41 |
| Profit before tax | 21 | 6 | 33 | 7 | 31 | 41 | 45 |
| Tax % | 28% | -1% | 28% | 10% | 26% | 25% | 30% |
| Net Profit + | 15 | 6 | 24 | 6 | 23 | 31 | 31 |
| EPS in Rs | 220.43 | 93.33 | 344.20 | 94.49 | 342.46 | 6.11 | 6.18 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Suraksha Diagnostic Ltd
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 10 | 10 |
| Reserves | 111 | 118 | 141 | 147 | 171 | 201 | 234 |
| Borrowings + | 13 | 18 | 21 | 99 | 92 | 89 | 130 |
| Other Liabilities + | 42 | 28 | 32 | 28 | 30 | 33 | 73 |
| Total Liabilities | 173 | 171 | 201 | 281 | 300 | 334 | 448 |
| Fixed Assets + | 128 | 119 | 119 | 195 | 212 | 223 | 316 |
| CWIP | 0 | 0 | 1 | 2 | 1 | 11 | 35 |
| Investments | 5 | 5 | 0 | 0 | 0 | 1 | 0 |
| Other Assets + | 39 | 46 | 80 | 84 | 87 | 99 | 97 |
| Total Assets | 173 | 171 | 201 | 281 | 300 | 334 | 448 |
Financials of Suraksha Diagnostic Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 31 | 24 | 42 | 44 | 60 | 63 | 82 |
| Cash from Investing Activity + | -20 | -28 | -44 | -21 | -35 | -40 | -52 |
| Cash from Financing Activity + | -10 | 3 | 1 | -24 | -25 | -24 | -29 |
| Net Cash Flow | 1 | -1 | -0 | -1 | 0 | -0 | 1 |
| Free Cash Flow | 15 | 8 | 23 | 32 | 18 | 21 | 15 |
| CFO/OP | 111% | 100% | 97% | 109% | 95% | 90% | 100% |
Financials of Suraksha Diagnostic Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 14 | 16 | 12 | 9 | 15 | 20 | 27 |
| Inventory Days | 93 | 62 | 38 | 82 | 89 | 100 | 81 |
| Days Payable | 227 | 177 | 84 | 187 | 193 | 169 | 209 |
| Cash Conversion Cycle | -120 | -99 | -34 | -96 | -89 | -49 | -101 |
| Working Capital Days | -35 | -19 | -15 | -49 | -37 | -23 | -28 |
| ROCE % | 8% | 23% | 9% | 17% | 18% | 17% |
Guidance history
How Suraksha Diagnostic Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Up 0–2% | Planned | — | — |
| Q3 FY26 call → | 20–40% | Up 0–2% | Planned | — | — |
| Q2 FY26 call → | 10–20% | Up 0–2% | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
35 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −1.7% | 60% |
| Last 6 months | +11.4% | 70% |
| Last 3 months | +25.5% | 91% |
The price is 24.2% below its all-time high of ₹417.25 (6 Dec 2024). Stocks more than 20% below their peak have their score halved, so 70 became 35.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Suraksha Diagnostic Ltd: 0.4 × 60 + 0.4 × 70 + 0.2 × 91 = 70, halved to 35 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.